The prevalence of pain in pediatric human immunodeficiency virus/acquired immunodeficiency syndrome as reported by participants in the Pediatric Late Outcomes Study (PACTG 219)

Denise M. Gaughan, Michael D. Hughes, George R. Seage, Peter A. Selwyn, Vincent J. Carey, Steven L. Gortmaker, James M. Oleske

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objectives. As the life expectancy of children with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) increases, quality-of-life outcomes are of increasing concern. The prevalence of pain in adults with AIDS ranges from 40% to 60%, depending on stage of illness. There is limited research concerning pain in HIV-infected children and youth. Design. The General Health Assessment for Children was administered to caregivers of HIV-infected children and youth enrolled in the Pediatric Late Outcomes Study (PACTG 219), a prospective cohort study. Pain is assessed over the previous month with 7 questions. For the purpose of this analysis, we defined pain as the presence of pain of at least moderate intensity. Participants were observed from January 1, 1996, to December 31, 1999. Results. A total of 985 HIV-positive participants had a baseline pain evaluation in 1995. The prevalence of pain remained relatively constant during each year of observation, averaging 20%. Lower CD4+ T-lymphocyte percentage, female gender, and an HIV/AIDS-related diagnosis were highly associated with an increased risk of reported pain. Pain was also independently associated with increased risk of death. After adjusting for CD4 percentage, use of combination therapy including protease inhibitors, comorbid diagnoses, and other sociodemographic characteristics, individuals reporting pain were over 5 times more likely to die than those not reporting pain (hazard ratio = 5.07; 95% confidence interval = 3.23-7.95). Conclusions. Pain is a frequently encountered symptom in children and youth with HIV disease and is also associated with increased mortality. These findings emphasize the importance of pain management in this population.

Original languageEnglish (US)
Pages (from-to)1144-1152
Number of pages9
JournalPediatrics
Volume109
Issue number6
DOIs
StatePublished - 2002

Fingerprint

Acquired Immunodeficiency Syndrome
Outcome Assessment (Health Care)
HIV
Pediatrics
Pain
Virus Diseases
Pain Management
Life Expectancy
Protease Inhibitors
Caregivers
Cohort Studies
Quality of Life
Observation
Prospective Studies
Confidence Intervals
T-Lymphocytes
Mortality
Research

Keywords

  • Generalized estimating equations
  • HIV/AIDS
  • Pain
  • Pediatrics
  • Proportional hazards regression
  • Protease inhibitors

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

The prevalence of pain in pediatric human immunodeficiency virus/acquired immunodeficiency syndrome as reported by participants in the Pediatric Late Outcomes Study (PACTG 219). / Gaughan, Denise M.; Hughes, Michael D.; Seage, George R.; Selwyn, Peter A.; Carey, Vincent J.; Gortmaker, Steven L.; Oleske, James M.

In: Pediatrics, Vol. 109, No. 6, 2002, p. 1144-1152.

Research output: Contribution to journalArticle

Gaughan, Denise M. ; Hughes, Michael D. ; Seage, George R. ; Selwyn, Peter A. ; Carey, Vincent J. ; Gortmaker, Steven L. ; Oleske, James M. / The prevalence of pain in pediatric human immunodeficiency virus/acquired immunodeficiency syndrome as reported by participants in the Pediatric Late Outcomes Study (PACTG 219). In: Pediatrics. 2002 ; Vol. 109, No. 6. pp. 1144-1152.
@article{5158ac0931924d8fbf44ee018fd66d46,
title = "The prevalence of pain in pediatric human immunodeficiency virus/acquired immunodeficiency syndrome as reported by participants in the Pediatric Late Outcomes Study (PACTG 219)",
abstract = "Objectives. As the life expectancy of children with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) increases, quality-of-life outcomes are of increasing concern. The prevalence of pain in adults with AIDS ranges from 40{\%} to 60{\%}, depending on stage of illness. There is limited research concerning pain in HIV-infected children and youth. Design. The General Health Assessment for Children was administered to caregivers of HIV-infected children and youth enrolled in the Pediatric Late Outcomes Study (PACTG 219), a prospective cohort study. Pain is assessed over the previous month with 7 questions. For the purpose of this analysis, we defined pain as the presence of pain of at least moderate intensity. Participants were observed from January 1, 1996, to December 31, 1999. Results. A total of 985 HIV-positive participants had a baseline pain evaluation in 1995. The prevalence of pain remained relatively constant during each year of observation, averaging 20{\%}. Lower CD4+ T-lymphocyte percentage, female gender, and an HIV/AIDS-related diagnosis were highly associated with an increased risk of reported pain. Pain was also independently associated with increased risk of death. After adjusting for CD4 percentage, use of combination therapy including protease inhibitors, comorbid diagnoses, and other sociodemographic characteristics, individuals reporting pain were over 5 times more likely to die than those not reporting pain (hazard ratio = 5.07; 95{\%} confidence interval = 3.23-7.95). Conclusions. Pain is a frequently encountered symptom in children and youth with HIV disease and is also associated with increased mortality. These findings emphasize the importance of pain management in this population.",
keywords = "Generalized estimating equations, HIV/AIDS, Pain, Pediatrics, Proportional hazards regression, Protease inhibitors",
author = "Gaughan, {Denise M.} and Hughes, {Michael D.} and Seage, {George R.} and Selwyn, {Peter A.} and Carey, {Vincent J.} and Gortmaker, {Steven L.} and Oleske, {James M.}",
year = "2002",
doi = "10.1542/peds.109.6.1144",
language = "English (US)",
volume = "109",
pages = "1144--1152",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6",

}

TY - JOUR

T1 - The prevalence of pain in pediatric human immunodeficiency virus/acquired immunodeficiency syndrome as reported by participants in the Pediatric Late Outcomes Study (PACTG 219)

AU - Gaughan, Denise M.

AU - Hughes, Michael D.

AU - Seage, George R.

AU - Selwyn, Peter A.

AU - Carey, Vincent J.

AU - Gortmaker, Steven L.

AU - Oleske, James M.

PY - 2002

Y1 - 2002

N2 - Objectives. As the life expectancy of children with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) increases, quality-of-life outcomes are of increasing concern. The prevalence of pain in adults with AIDS ranges from 40% to 60%, depending on stage of illness. There is limited research concerning pain in HIV-infected children and youth. Design. The General Health Assessment for Children was administered to caregivers of HIV-infected children and youth enrolled in the Pediatric Late Outcomes Study (PACTG 219), a prospective cohort study. Pain is assessed over the previous month with 7 questions. For the purpose of this analysis, we defined pain as the presence of pain of at least moderate intensity. Participants were observed from January 1, 1996, to December 31, 1999. Results. A total of 985 HIV-positive participants had a baseline pain evaluation in 1995. The prevalence of pain remained relatively constant during each year of observation, averaging 20%. Lower CD4+ T-lymphocyte percentage, female gender, and an HIV/AIDS-related diagnosis were highly associated with an increased risk of reported pain. Pain was also independently associated with increased risk of death. After adjusting for CD4 percentage, use of combination therapy including protease inhibitors, comorbid diagnoses, and other sociodemographic characteristics, individuals reporting pain were over 5 times more likely to die than those not reporting pain (hazard ratio = 5.07; 95% confidence interval = 3.23-7.95). Conclusions. Pain is a frequently encountered symptom in children and youth with HIV disease and is also associated with increased mortality. These findings emphasize the importance of pain management in this population.

AB - Objectives. As the life expectancy of children with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) increases, quality-of-life outcomes are of increasing concern. The prevalence of pain in adults with AIDS ranges from 40% to 60%, depending on stage of illness. There is limited research concerning pain in HIV-infected children and youth. Design. The General Health Assessment for Children was administered to caregivers of HIV-infected children and youth enrolled in the Pediatric Late Outcomes Study (PACTG 219), a prospective cohort study. Pain is assessed over the previous month with 7 questions. For the purpose of this analysis, we defined pain as the presence of pain of at least moderate intensity. Participants were observed from January 1, 1996, to December 31, 1999. Results. A total of 985 HIV-positive participants had a baseline pain evaluation in 1995. The prevalence of pain remained relatively constant during each year of observation, averaging 20%. Lower CD4+ T-lymphocyte percentage, female gender, and an HIV/AIDS-related diagnosis were highly associated with an increased risk of reported pain. Pain was also independently associated with increased risk of death. After adjusting for CD4 percentage, use of combination therapy including protease inhibitors, comorbid diagnoses, and other sociodemographic characteristics, individuals reporting pain were over 5 times more likely to die than those not reporting pain (hazard ratio = 5.07; 95% confidence interval = 3.23-7.95). Conclusions. Pain is a frequently encountered symptom in children and youth with HIV disease and is also associated with increased mortality. These findings emphasize the importance of pain management in this population.

KW - Generalized estimating equations

KW - HIV/AIDS

KW - Pain

KW - Pediatrics

KW - Proportional hazards regression

KW - Protease inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0036264425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036264425&partnerID=8YFLogxK

U2 - 10.1542/peds.109.6.1144

DO - 10.1542/peds.109.6.1144

M3 - Article

VL - 109

SP - 1144

EP - 1152

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 6

ER -